Yes, Vyepti (eptinezumab) is a biologic medication. It is a monoclonal antibody, meaning it’s a lab-engineered protein designed to target a specific molecule in the body. Specifically, Vyepti blocks calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. The FDA approved it on February 21, 2020, for the preventive treatment of migraine in adults.
What Makes Vyepti a Biologic
Biologics are medications made from living cells rather than through chemical synthesis like traditional pills. Vyepti is produced using a yeast-based system (Pichia pastoris), which grows the antibody protein in living organisms. This is a hallmark of biologic drugs: they’re large, complex proteins that can only be manufactured by harnessing biological processes, not assembled in a chemistry lab.
Because Vyepti is a biologic, it’s regulated under a different FDA pathway than conventional drugs. Its application number starts with “761,” which designates a Biologics License Application (BLA) rather than a standard New Drug Application. This distinction matters if you’re ever looking at generic or biosimilar options down the road, since biologics don’t get traditional generics. Instead, they get biosimilars, which must meet a separate set of approval standards. No biosimilars for Vyepti are currently available.
How Vyepti Works
Vyepti belongs to a class of biologics known as CGRP antagonists. CGRP is a signaling protein that spikes during migraine attacks and plays a key role in pain transmission and blood vessel dilation in the brain. Vyepti binds directly to the CGRP molecule itself, neutralizing it before it can activate its receptor and trigger migraine symptoms.
This is a preventive approach, not an acute treatment. The goal is to reduce how many migraine days you experience each month by keeping CGRP levels in check on an ongoing basis.
How Vyepti Compares to Other CGRP Biologics
Vyepti is one of four monoclonal antibody biologics that target the CGRP pathway for migraine prevention. The others are Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab). All four are biologics, but they differ in a few practical ways.
The biggest difference is how you receive them. Vyepti is the only one given as an intravenous (IV) infusion, which takes about 30 minutes in a healthcare setting every 3 months. The other three are self-administered injections at home: Aimovig is a monthly injection, Emgality is a monthly injection after an initial loading dose, and Ajovy can be taken as a monthly injection or a quarterly injection.
Another difference is what they target. Aimovig blocks the CGRP receptor, while Vyepti, Ajovy, and Emgality all bind to the CGRP protein itself. In practice, all four have shown meaningful results in clinical trials, so the choice often comes down to whether you prefer at-home injections or quarterly infusions, along with insurance coverage.
What the Infusion Looks Like
Because Vyepti is a biologic given by IV, you’ll receive it at a clinic, infusion center, or doctor’s office. The standard dose is 100 mg every 3 months, though some patients receive 300 mg if the lower dose isn’t providing enough relief. The infusion itself takes roughly 30 minutes, and then you’re typically observed briefly before heading home.
For some people, the quarterly schedule is a major advantage. Rather than remembering a monthly injection, you visit four times a year and don’t need to handle needles at home. Others find the requirement to go to a medical facility less convenient than self-injecting.
How Well It Works
In the PROMISE-2 clinical trial, which studied Vyepti in people with chronic migraine (15 or more headache days per month), both doses significantly reduced monthly migraine days over a 12-week period. People receiving the 100 mg dose had an average reduction of 7.7 migraine days per month, and the 300 mg group saw a reduction of 8.2 days per month. The placebo group had a reduction of 5.6 days. That means Vyepti provided roughly 2 to 2.6 additional migraine-free days per month beyond what a placebo achieved.
Side Effects
Vyepti has a relatively mild side effect profile. In clinical trials, the most common adverse reactions were nasopharyngitis (a stuffy or runny nose, similar to a mild cold) and hypersensitivity reactions. Nasopharyngitis occurred in 6% to 8% of patients on Vyepti, which was similar to the 6% rate seen in the placebo group. Hypersensitivity reactions, including flushing, itching, or allergic-type symptoms on the day of infusion, occurred in 1% to 2% of patients on Vyepti compared to 0% on placebo.
Because it’s a biologic delivered by IV, there is always a small risk of infusion-related reactions, which is one reason the infusion is done in a medical setting where staff can monitor you.